Get the Stockscreener App
54.85
10.24%
-6.26
Nektar Therapeutics stock is traded at $54.85, with a volume of 658.88K.
It is down -10.24% in the last 24 hours and down -15.52% over the past month.
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
See More
Previous Close:
$61.11
Open:
$61.11
24h Volume:
658.88K
Relative Volume:
0.68
Market Cap:
$1.12B
Revenue:
$90.12M
Net Income/Loss:
$-276.06M
P/E Ratio:
-37.57
EPS:
-1.46
Net Cash Flow:
$-193.47M
1W Performance:
-9.11%
1M Performance:
-15.52%
6M Performance:
+6,787%
1Y Performance:
+4,548%
1-Day Range:
$54.65
$61.40
1-Week Range:
$54.65
$66.86
52-Week Range:
$0.432
$66.92
Nektar Therapeutics Stock (NKTR) Company Profile
Name
Nektar Therapeutics
Sector
Industry
Phone
(415) 482-5300
Address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
54.85 | 1.24B | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.15 | 107.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
742.00 | 78.84B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.93 | 60.05B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
915.36 | 55.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.60 | 45.09B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-25 | Initiated | Citigroup | Buy |
| Jun-24-25 | Reiterated | BTIG Research | Buy |
| Jun-24-25 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-14-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-08-25 | Initiated | B. Riley Securities | Buy |
| Dec-10-24 | Initiated | H.C. Wainwright | Buy |
| Nov-04-24 | Initiated | Piper Sandler | Overweight |
| Sep-30-24 | Resumed | BTIG Research | Buy |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Nov-09-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| May-10-23 | Upgrade | Jefferies | Underperform → Hold |
| Feb-24-23 | Downgrade | Jefferies | Hold → Underperform |
| Aug-08-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-31-22 | Resumed | Jefferies | Hold |
| Apr-18-22 | Downgrade | Goldman | Neutral → Sell |
| Mar-15-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-15-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-14-22 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-14-22 | Downgrade | Stifel | Buy → Hold |
| Mar-14-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-09-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-08-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Sep-10-21 | Initiated | BofA Securities | Neutral |
| Jun-28-21 | Upgrade | Stifel | Hold → Buy |
| May-18-21 | Resumed | Goldman | Neutral |
| Feb-22-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jan-06-21 | Initiated | Stifel | Hold |
| Sep-14-20 | Initiated | JP Morgan | Neutral |
| Jun-10-20 | Downgrade | CFRA | Hold → Sell |
| May-12-20 | Reiterated | H.C. Wainwright | Neutral |
| Apr-22-20 | Initiated | The Benchmark Company | Buy |
| Mar-30-20 | Upgrade | Goldman | Sell → Neutral |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-03-20 | Upgrade | Mizuho | Neutral → Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-08-19 | Downgrade | Goldman | Buy → Sell |
| Aug-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-09-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-09-19 | Downgrade | Mizuho | Buy → Neutral |
| Mar-15-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-13-18 | Initiated | Goldman | Buy |
| Jun-11-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-04-18 | Reiterated | H.C. Wainwright | Buy |
| Apr-20-18 | Initiated | Seaport Global Securities | Buy |
| Apr-13-18 | Resumed | Piper Jaffray | Overweight |
| Apr-06-18 | Reiterated | Mizuho | Buy |
| Apr-02-18 | Resumed | H.C. Wainwright | Buy |
View All
Nektar Therapeutics Stock (NKTR) Latest News
How robust is Nektar Therapeutics (ITH0) stock financial position2025 Institutional Moves & Free Daily Entry Point Trade Alerts - Newser
Is Nektar Therapeutics stock attractive for ETFs2025 Winners & Losers & Long-Term Growth Stock Strategies - Newser
How strong dollar benefits Nektar Therapeutics (ITH0) stockTrade Signal Summary & Free Real-Time Market Sentiment Alerts - Newser
Will Nektar Therapeutics stock benefit from upcoming earnings reportsBreakout Watch & Low Drawdown Momentum Ideas - Newser
Colorectal Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | Takeda, Genentech/Seagen, AstraZeneca and Daiichi Sankyo, Merck, Amgen, Daiichi Sankyo Company, Mirati Therapeu - Barchart.com
ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors - The Manila Times
ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors - GlobeNewswire Inc.
Latex Allergy Market Covering Prime Factors and Competitive - openPR.com
Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade - Finviz
Nektar Therapeutics Reveals Promising Phase 2b Trial Results - MSN
Nektar Therapeutics Reports Second Quarter 2025 Financial Results (PR Newswire) - Aktiellt
Jefferies Maintains Nektar Therapeutics (NKTR) Buy Recommendation - Nasdaq
Citigroup Initiates Coverage on NKTR with 'Buy' Rating | NKTR St - GuruFocus
Jefferies Raises Nektar Therapeutics (NKTR) Price Target to $121 - GuruFocus
Nektar Therapeutics R (ITH0.MU) Q2 FY2025 earnings call transcript - Yahoo Finance
Nektar Therapeutics CEO sells $119,795 in shares By Investing.com - Investing.com South Africa
Citi starts Nektar with Buy, opens ‘positive catalyst watch’ - TipRanks
Nektar (NKTR) Receives Buy Rating with Positive Outlook from Cit - GuruFocus
Citi Initiates Nektar Therapeutics(NKTR.US) With Buy Rating, Announces Target Price $102 - 富途牛牛
Nektar Therapeutics chief R&D officer sells $62,801 in stock By Investing.com - Investing.com Australia
Nektar Therapeutics CLO Wilson sells $34,196 in shares By Investing.com - Investing.com South Africa
Nektar Therapeutics Announces Pricing of $100 Million Public Offering (PR Newswire) - Aktiellt
Nektar Therapeutics chief R&D officer sells $62,801 in stock - Investing.com
Nektar Therapeutics CLO Wilson sells $34,196 in shares - Investing.com
How Investors May Respond To Nektar Therapeutics (NKTR) Clinical Progress and Leadership Transition - simplywall.st
Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $105 - 富途牛牛
Nektar Therapeutics stock price target raised to $121 from $99 at Jefferies - Investing.com Nigeria
Nektar Therapeutics (NKTR) PT Raised to $121 at Jefferies - StreetInsider
Assessing Nektar Therapeutics (NKTR) Valuation Following Recent Share Price Surge - simplywall.st
Nektar Therapeutics Stock Analysis and ForecastInsider Buying Signals & Stay One Step Ahead of Risk Events - earlytimes.in
Is Nektar Therapeutics (NKTR) The Hottest SMID-Cap Stock to Buy Now? - Finviz
Nektar Therapeutics announces chief legal officer transition effective year-end By Investing.com - Investing.com India
Nektar Therapeutics Announces Chief Legal Officer Departure - TipRanks
Nektar Therapeutics announces chief legal officer transition effective year-end - Investing.com
Nektar Therapeutics Announces Chief Legal Officer Change - TradingView
Rezpegaldesleukin Shows Strong Phase 2b Results for Atopic Dermatitis, Asthma - HCPLive
Can Nektar Therapeutics (ITH0) stock stage a strong rebound this quarterMarket Risk Summary & Daily Market Momentum Tracking - newser.com
Will Nektar Therapeutics (ITH0) stock beat Nasdaq index returns2025 Investor Takeaways & AI Enhanced Trading Signals - newser.com
Nektar at Jefferies: Biologics in Focus for New Indications By Investing.com - Investing.com Australia
Nektar at Jefferies: Biologics in Focus for New Indications - Investing.com
Nektar Therapeutics (NKTR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How big funds are accumulating Nektar Therapeutics (ITH0) stockMarket Rally & Long-Term Safe Investment Ideas - newser.com
Will Nektar Therapeutics (ITH0) stock profit from fiscal stimulusWeekly Risk Summary & AI Optimized Trading Strategy Guides - newser.com
Is Nektar Therapeutics stock attractive for passive investorsJuly 2025 EndofMonth & AI Powered Trade Plan Recommendations - newser.com
How Nektar Therapeutics (ITH0) stock trades in high volatilityMarket Risk Analysis & Safe Entry Zone Tips - newser.com
What RSI levels show for Nektar Therapeutics (ITH0) stock2025 Major Catalysts & Capital Efficiency Focused Strategies - newser.com
Is it time to cut losses on Nektar TherapeuticsJuly 2025 Highlights & Verified Entry Point Signals - newser.com
Nektar Therapeutics Stock (NKTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
1.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):